Ginkgo Bioworks Holdings (DNA) Gross Profit (2020 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly Gross Profit came in at $16.4 million in Q1 2026, down 52.03% YoY from $34.1 million in Q1 2025, and up 13.1% on a QoQ basis from $14.5 million in Q4 2025.
Ginkgo Bioworks Holdings (DNA) Gross Profit (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 7 years of Gross Profit data on file, last reported at $16.4 million in Q1 2026.
- Quarterly Gross Profit fell 52.03% year-over-year to $16.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $105.7 million (down 51.33% YoY) and the FY2025 annual result came in at $141.3 million, down 36.1% from the prior year.
- Gross Profit grew to $16.4 million in Q1 2026, from $14.5 million in the prior quarter.
- In the past five years, Gross Profit ranged from a high of $251.6 million in Q4 2022 to a low of $14.5 million in Q4 2025.
- A 5-year average of $81.4 million and a median of $48.5 million in 2023 frame the typical range for Gross Profit.
- Annual changes were most pronounced in 2022 — Gross Profit jumped 428.52% — and 2024, when it sank 83.33%.
- Tracing DNA's Gross Profit over 5 years: stood at $251.6 million in 2022, then slipped by 0.43% to $250.6 million in 2023, then slumped by 83.33% to $41.8 million in 2024, then slumped by 65.34% to $14.5 million in 2025, then climbed by 13.1% to $16.4 million in 2026.
- The last three Gross Profit figures came in at $16.4 million (Q1 2026), $14.5 million (Q4 2025), and $30.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ginkgo Bioworks Holdings | 432.60 Mn | 348.06 Mn | 18.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.44 Mn |
| Jun 30, 2026 | 18.44 Mn |
| Mar 31, 2026 | 16.38 Mn |
| Mar 31, 2026 | 16.38 Mn |
| Dec 31, 2025 | 14.48 Mn |
| Dec 31, 2025 | 14.48 Mn |
| Sep 30, 2025 | 30.66 Mn |
| Sep 30, 2025 | 30.66 Mn |
| Jun 30, 2025 | 44.22 Mn |
| Jun 30, 2025 | 44.22 Mn |
| Mar 31, 2025 | 34.14 Mn |
| Mar 31, 2025 | 34.14 Mn |
| Dec 31, 2024 | 41.78 Mn |
| Dec 31, 2024 | 41.78 Mn |
| Sep 30, 2024 | 87.03 Mn |
| Sep 30, 2024 | 87.03 Mn |
| Jun 30, 2024 | 54.29 Mn |
| Jun 30, 2024 | 54.29 Mn |
| Mar 31, 2024 | 37.94 Mn |
| Mar 31, 2024 | 37.94 Mn |